Chimerix to Present Q3 2024 Financial Results and Updates
Chimerix (NASDAQ: CMRX), a biopharmaceutical company focused on developing innovative therapies, has announced an upcoming live conference call aimed at discussing their financial results for the third quarter of 2024. This event will take place on a Thursday morning, and it is a vital moment for stakeholders keen to understand the implications of the company’s development endeavors.
Details of the Upcoming Conference Call
The live conference call will be accessible to investors and interested parties, featuring important discussions on the operational status and financial health of Chimerix. To participate, attendees should dial (646) 307-1963 for domestic calls or (800) 715-9871 for international calls. It’s recommended that callers join the line at least five minutes prior to the scheduled start time, where the conference ID necessary for access is 6580777.
Webcast Availability
In addition to the conference call, Chimerix will host a live audio webcast, expanding access to those who prefer to participate digitally. This will be available through the Investors’ section of their official website, ensuring broader reach for investors and the public. For those unable to attend live, an archived version will be accessible approximately two hours post-event.
Chimerix’s Mission and Current Leadership
Dedicated to developing medicines that can significantly enhance and prolong the lives of patients confronting serious diseases, Chimerix continues to make strides in the biopharmaceutical landscape. The focus of their clinical endeavors includes ONC201, which targets the aggressive H3 K27M-mutant diffuse glioma, showcasing their innovative approach to oncology.
Investigation into ONC206
Chimerix is also pursuing its Phase 1 dose escalation studies of ONC206, with the objective of analyzing safety profiles and pharmacokinetics. This research is critical as it lays the foundational groundwork for future developments and potential treatment options for patients.
Company Contact Information
For inquiries related to investor relations, Will O’Connor from Stern Investor Relations is the point of contact. He can be reached at 212-362-1200 or through email for more detailed discussions.
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The call is intended to present the financial results for Q3 2024 and provide operational insights regarding Chimerix's projects.
When is the conference call scheduled?
The conference call is set for November 7, 2024, at 8:30 a.m. ET.
How can I access the live conference?
You can participate by dialing the provided numbers or through the audio webcast on the company's official site.
What are some of Chimerix's notable programs?
Chimerix focuses on developing ONC201 and is conducting studies on ONC206 as part of its clinical research initiatives.
Who can I contact for more information?
For further details, you can reach out to Will O'Connor from Stern Investor Relations at the listed phone number or via email.